Together with tau tangles, the presence of amyloid in the brain is a key marker of Alzheimer's disease, a condition with no cure that is estimated to impact more than 7.4 million Americans by 2025.1 Improving the ability of practicing clinicians to detect evidence of amyloid is an important step in being able to effectively manage the disease. Currently, healthcare providers can find evidence of amyloid in the living brain through two methods: a cerebrospinal fluid (CSF) test and an amyloid brain positron emission tomography (PET) scan.
Lilly and Roche Diagnostics to Collaborate on Alzheimer's Disease Adjunct Diagnostic Tool (NYSE:LLY)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.